

---

## CORRECTIONS



**Schaller M, Kemény L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. *J Am Acad Dermatol.* 2020;82(2):336-43.**

In the article above an incorrect *P* value printed in the legend to Fig 2. The final *P* value listed should have been .032 rather than .32. The correction has been made to the article online.



**Marzano AV, Genovese G, Tavecchio S, et al. Clinical and immunopathologic features of idiopathic cutaneous immunoglobulin M/G vasculitis versus idiopathic skin-limited immunoglobulin A vasculitis. *J Am Acad Dermatol.* 2021;84(1):175-178.**

In the article above, a sentence in the first paragraph on page 178 should have read as follows: “The mean latency time between onset of vasculitis and achievement of CR in patients receiving systemic treatment was significantly higher in sl-IgAV than in c-IgM/IgGV (12.9 vs. 9.5 months, respectively; *P* = .01).” The online version of the article has been updated.